

Use of Data Science & Digital Technologies in Regulatory Affairs

/////////

Dr. Patrick Brady VP and Head, Regulatory Policy & Intelligence Bayer AG



8 November 2019



Agenda

- Opportunity of Data Science & Digital Technologies
- Digital Technologies in Drug Development – selected case studies



Opportunity of Data Science & Digital Technologies



Advances in data science and digital technologies are contributing to a changing landscape in pharma





Interdisciplinary field focused on extracting insights from data



Copyright © 2014 by Steven Geringer Raleigh, NC. Permission is granted to use, distribute, or modify this image, provided that this copyright notice remains intact.



6

Data science uses a range of technologies to solve increasingly complex challenges in a data-driven manner



Data science can augment human intelligence

Leveraging strengths of machines and humans results in increased effectiveness



ANTICIPATION



Several factors fueling recent advances in artificial intelligence





numOfdot ID.capitalize place("czFormat", :02x}".format(ord(c) String.replace(oin("{:02x}".format(ent) string4replace • st = line print(- - kDi cha

Increasing volume of data

Faster, cheaper processing

Smarter algorithms



Digital Technologies in Drug Development – selected case studies

Technology is helping drug development stakeholders in several ways:

PHYSICIANS

supporting diagnosis of diseases through image analysis

PATIENTS

2

3

facilitating use of drugs by providing information and reminders

REGULATORY AFFAIRS

supporting development strategies and compliance by analyzing regulatory environment and decisions

Bayer is developing artificial intelligence software to help physicians diagnose CTEPH through pattern recognition





- Software will use deep learning to support radiologists by identifying signs of CTEPH in computed tomography pulmonary angiography (CTPA) scans
- Software processes image findings of cardiovascular, lung perfusion and pulmonary vessel analyses in combination with the patient's history of pulmonary embolism
- Software could be deployed via Bayer's Radimetrics[™], an informatics technology platform that connects contrast medium with injector and scan information to provide important insights
- Received FDA's Breakthrough Device Designation in 2018

BAYER

12

An alternate solution to help women manage a flexible dosing regimen for contraception



- Contraceptive with a flexible dosing regimen
- App guides women through the flexible regimen, allowing women to decide when to have their menstrual bleeding and what to do in case of missed pills
- Contains complete labeling of product
- Package refers patients to download the app





Technology is helping Bayer monitor the regulatory context and requirements





Updates on regulatory context & requirements

- News (press, speeches, etc.)
- Laws, regulations, guidance

 Automatic monitoring of relevant sources and topics

Communicated

through a dashboard &

newsletter

Can increase efficiency

- Reduced manual effort for monitoring
- Improved information flow for users



Technology is also helping Bayer better understand regulatory decision making





- Clinical trial information
- Regulatory
 assessment reports
- Competitor labels

- Designed to answer many types of questions
- More efficient search
- New insights can help increase efficiency of drug development
- Improved prediction of challenges and regulatory approval





Data from an even broader range of data sources will be utilized to inform decision making



Algorithms and processing power will continue to advance rapidly



Data science and digital technologies will be applied to additional use cases, which will help bring innovative treatments to patients faster

What impact will machine learning have on jobs?

- Substitution may substitute for humans in some tasks
- Price elasticity may lower cost of certain tasks, which could impact spending
- Complementarities demand for other tasks may increase
- Income elasticity compensation may increase for tasks in high demand
- Elasticity of labor supply as wages change for specific task, number of workers changes
- Business process redesign processes will change to increase efficiency



Al technology has potential to augment Regulatory Affairs knowledge, resulting in increased efficiency

BAYER





- Data science uses a range of technologies to solve increasingly complex challenges in a data-driven manner
- Physicians, patients, regulatory affairs colleagues, and regulators are using digital technologies to transform how they engage at several stages of the drug development process. These technologies represent a significant opportunity to increase the efficiency and effectiveness of drug development.
- Collaboration & trust will be critical as stakeholders look to apply data science and digital technologies to address additional challenges in drug development



Thank you!

